Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Russano

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Thoracic Cancer|February 2, 2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter studyAlessio Cortellini, Andrea De Giglio, Katia Cannita, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Thoracic Cancer|February 2, 2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter studyAlessio Cortellini, Andrea De Giglio, Katia Cannita, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Pageof 8